BioSante Pharmaceuticals, Inc. Comments On Updated FDA Guidance For Testosterone Therapy

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nov. 2, 2005--BioSante Pharmaceuticals (AMEX:BPA) today offered comment on updated U.S. Food and Drug Administration (FDA) safety and efficacy guidance for the development of testosterone products for the treatment of female hypoactive sexual desire disorder (HSDD). The new guidance was announced on Saturday, October 29 at the International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting in Las Vegas, during a presentation by Dr. Daniel Shames, Director of the FDA's Division of Reproductive and Urologic Products.